Radich Jerald P, Mauro Michael J
Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D4-100, Seattle, WA 98104, USA.
Myeloproliferative Neoplasms Program, Leukemia Section, Memorial Sloan Kettering Cancer Center, 1275 York Avenue (Between 67th and 68th street), New York, NY 10065, USA.
Hematol Oncol Clin North Am. 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder that accounts for approximately 10% of new cases of leukemia. The introduction of tyrosine kinase inhibitors has led to a reduction in mortalities. Thus, the estimated prevalence of CML is increasing. The National Comprehensive Cancer Network and the European Leukemia Net guidelines incorporate frequent molecular monitoring of the fusion BCR-ABL transcript to ensure that patients reach and keep treatment milestones. Most patients with CML are diagnosed in the chronic phase, and approximately 10% to 30% of these patients will at some time in their course meet definition criteria of resistance to imatinib.
慢性髓性白血病（CML）是一种骨髓增殖性疾病，约占白血病新发病例的10%。酪氨酸激酶抑制剂的引入已导致死亡率下降。因此，CML的估计患病率正在上升。美国国立综合癌症网络和欧洲白血病网的指南纳入了对融合BCR-ABL转录本的频繁分子监测，以确保患者达到并维持治疗里程碑。大多数CML患者在慢性期被诊断出来，其中约10%至30%的患者在病程中的某个时候将符合对伊马替尼耐药的定义标准。
